All women (N = 175) % (95% CI) | HIV-1 seropositive women (N = 94) % (95% CI) | HIV seronegative women (N = 81) % (95% CI) | * P-value | |
---|---|---|---|---|
hr-HPV prevalence | 55.0 (48.0–62.9) | 79.0 (69.0–86.5) | 28.0 (19.0–39.5) | 0.0001 |
Sensitivity | 96.9 (91.2–99.4) | 97.3 (90.6–99.7) | 95.7 (78.1–99.9) | 0.50 |
Specificity | 91.0 (82.4–96.3) | 85.0 (62.1–96.8) | 93.1 (83.3–98.1) | 0.10 |
PPV | 93.1 (86.2–97.2) | 96.0 (88.8–99.2) | 84.6 (65.1–95.6) | 0.01 |
NPV | 95.9 (88.8–99.2) | 89.5 (66.9–98.7) | 98.2 (90.3–100.0) | 0.02 |
Agreement | 94.3 (89.7–97.2) | 94.7 (88.0–98.3) | 93.8 (86.2–98.0) | 0.77 |
Kappa value (95%CI) | 0.88 (0.81–0.95) | 0.84 (0.70–0.98) | 0.85 (0.73–0.98) | 0.86 |
P-value for Kappa | <0.0001 | <0.0001 | <0.0001 |